Advaxis, Inc. (ADXS) Analysts See $-0.41 EPS; Duff & Phelps Select Energy Mlp Fund (DSE) SI Increased By 118.75%

May 13, 2018 - By Vivian Park

Advaxis, Inc. (NASDAQ:ADXS) Logo

Analysts expect Advaxis, Inc. (NASDAQ:ADXS) to report $-0.41 EPS on June, 5.They anticipate $0.10 EPS change or 19.61% from last quarter’s $-0.51 EPS. After having $-0.49 EPS previously, Advaxis, Inc.’s analysts see -16.33% EPS growth. The stock increased 8.54% or $0.14 during the last trading session, reaching $1.78. About 1.14 million shares traded or 21.14% up from the average. Advaxis, Inc. (NASDAQ:ADXS) has declined 77.70% since May 13, 2017 and is downtrending. It has underperformed by 89.25% the S&P500.

Duff & Phelps Select Energy Mlp Fund Inc (NYSE:DSE) had an increase of 118.75% in short interest. DSE’s SI was 484,100 shares in May as released by FINRA. Its up 118.75% from 221,300 shares previously. With 168,500 avg volume, 3 days are for Duff & Phelps Select Energy Mlp Fund Inc (NYSE:DSE)’s short sellers to cover DSE’s short positions. The stock increased 1.41% or $0.08 during the last trading session, reaching $5.76. About 29,905 shares traded. Duff & Phelps Select Energy MLP Fund Inc. (NYSE:DSE) has 0.00% since May 13, 2017 and is . It has underperformed by 11.55% the S&P500.

Another recent and important Duff & Phelps Select Energy MLP Fund Inc. (NYSE:DSE) news was published by Prnewswire.com which published an article titled: “Duff & Phelps Select Energy MLP Fund Inc. Declares Quarterly Distribution of $0.15 per Share” on May 01, 2018.

Duff & Phelps Select Energy MLP Fund Inc. is a closed-ended equity mutual fund launched by Virtus Investment Partners, Inc. The company has market cap of $. The fund is co-managed by Duff & Phelps Investment Management Co. and Virtus Alternative Investment Advisers, Inc. It currently has negative earnings. It invests in the public equity markets of the United States.

Among 4 analysts covering Advaxis (NASDAQ:ADXS), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Advaxis had 10 analyst reports since September 11, 2015 according to SRatingsIntel. H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) on Wednesday, November 8 with “Buy” rating. The stock of Advaxis, Inc. (NASDAQ:ADXS) earned “Overweight” rating by Barclays Capital on Tuesday, September 22. The firm earned “Buy” rating on Wednesday, June 14 by H.C. Wainwright. The company was maintained on Monday, June 12 by Cantor Fitzgerald. On Thursday, July 6 the stock rating was maintained by Cantor Fitzgerald with “Buy”. The firm has “Overweight” rating given on Tuesday, March 13 by Cantor Fitzgerald. As per Wednesday, March 14, the company rating was maintained by H.C. Wainwright. The company was maintained on Wednesday, May 31 by Cantor Fitzgerald. H.C. Wainwright maintained Advaxis, Inc. (NASDAQ:ADXS) on Wednesday, December 27 with “Buy” rating. As per Friday, September 11, the company rating was initiated by Guggenheim.

Since December 29, 2017, it had 0 insider buys, and 3 sales for $20,259 activity. Shares for $94 were sold by LOMBARDO ANTHONY A. Bonstein Sara also sold $16,612 worth of Advaxis, Inc. (NASDAQ:ADXS) shares. Another trade for 2,193 shares valued at $3,553 was sold by PETIT ROBERT.

Another recent and important Advaxis, Inc. (NASDAQ:ADXS) news was published by Businesswire.com which published an article titled: “Recently Presented Preclinical Data Show Potential for ADXS-NEO as Anti-Cancer Immunotherapy Agent” on May 11, 2018.

Advaxis, Inc., a clinical stage biotechnology company, focuses on the discovery, development, and commercialization of Lm-LLO cancer immunotherapies in the United States. The company has market cap of $93.12 million. The Company’s lead product Axalimogene filolisbac, an Lm-LLO immunotherapy product candidate, which completed its Phase II study for the treatment of human papilloma virus associated cancers, including cervical, head and neck, and anal cancer. It currently has negative earnings. The firm is also developing ADXS-PSA, an Lm-LLO immunotherapy product candidate, which is in Phase I/II clinical trials designed to target the prostate specific antigen associated with prostate cancer; and ADXS-HER2, an Lm-LLO immunotherapy product candidate that is in Phase Ib clinical trials used for the treatment of human epidermal growth factor receptor 2 expressing cancers, including human and canine osteosarcoma.

Advaxis, Inc. (NASDAQ:ADXS) Institutional Positions Chart

- Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

By

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our FREE daily email newsletter:


Recent Posts

>